Impact of Cognitive Profile on Impulse Control Disorders Presence and Severity in Parkinson's Disease by Martini, A et al.
ORIGINAL RESEARCH
published: 22 March 2019
doi: 10.3389/fneur.2019.00266
Frontiers in Neurology | www.frontiersin.org 1 March 2019 | Volume 10 | Article 266
Edited by:
Oury Monchi,
University of Calgary, Canada
Reviewed by:
John C. Dalrymple-Alford,
University of Canterbury, New Zealand
Emilia Gatto,
Sanatorio de la Trinidad Mitre,
Argentina
*Correspondence:
Roberta Biundo
roberta.biundo@yahoo.it
Specialty section:
This article was submitted to
Movement Disorders,
a section of the journal
Frontiers in Neurology
Received: 10 October 2018
Accepted: 27 February 2019
Published: 22 March 2019
Citation:
Martini A, Weis L, Fiorenzato E,
Schifano R, Cianci V, Antonini A and
Biundo R (2019) Impact of Cognitive
Profile on Impulse Control Disorders
Presence and Severity in Parkinson’s
Disease. Front. Neurol. 10:266.
doi: 10.3389/fneur.2019.00266
Impact of Cognitive Profile on
Impulse Control Disorders Presence
and Severity in Parkinson’s Disease
Alice Martini 1, Luca Weis 2, Eleonora Fiorenzato 2, Roberta Schifano 2, Valeria Cianci 2,
Angelo Antonini 3 and Roberta Biundo 2*
1 School of Psychology, Keele University, Newcastle-under-Lyme, United Kingdom, 2 IRCCS San Camillo Hospital, Venice,
Italy, 3Department of Neuroscience (DNS), University of Padua, Padua, Italy
Background: Impulse control disorders (ICDs) and related behaviors are frequent in
Parkinson’s disease (PD). Mild cognitive impairment (PD-MCI) and dementia (PDD), both
characterized by heterogeneous cognitive phenotypes, are also commonly reported in
PD. However, the frequency and severity of ICD within PD cognitive states is unknown.
Methods: Three hundred and twenty-six PD patients completed a comprehensive
neuropsychological assessment and were classified as PD-MCI, PDD, or without
cognitive alterations (PD-NC). The Minnesota impulsive disorders interview was used
to ascertain the presence (ICD+) or absence (ICD–) of ICD. The Questionnaire for
Impulsive-Compulsive Disorders in Parkinson’s Disease-Rating Scale was used to assess
ICD severity. A subsample of 286 patients evaluated with the same cognitive tasks was
selected in order to investigate the characteristics of ICD in PD cognitive phenotypes.
Results: ICDs were present in 55% of PD-NC, in 50% of PD-MCI, and in 42% of PDD
patients. Frequencies of ICD+ with attentive (ICD+: 20% vs. ICD–: 4%; p = 0.031) and
executive impairments (ICD+: 44% vs. ICD–: 30%; p= 0.027) were higher in the PD-MCI
and PDD subgroups, respectively. As expected, no differences were observed in the
PD-NC. PD-MCI with attentive impairments presented higher percentage of ICD+ with
deficits in the Trail Making Test B-A but not in the Digit Span Sequencing task. In PDD,
executive failures concerned Similarities task (ICD+: 67%; ICD–: 29%; p = 0.035), with
no differences between ICD+ and ICD– in the Stroop task.
Conclusions: Prevalence and severity of ICDs and related behaviors do not differ
in PD with different cognitive states. However, ICD+ are more likely to show deficits,
respectively in attentive and in executive domains, specifically in the Trail Making Test
B-A task for the attention and working memory domain in PD-MCI and in the Similarities
task for the executive function domain in PDD. Prospective studies should evaluate if
these tests can be used as screening tool for ICDs in PD.
Keywords: Parkinson’s disease, mild cognitive impairment, dementia, impulse control disorder, cognitive profile,
cognition, cognitive states, cognitive phenotypes
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INTRODUCTION
In Parkinson’s disease (PD), impulse control disorders (ICDs) are
reported in around 30% ofmedicated patients (1, 2). They include
pathological gambling (PG), hypersexuality (HS), compulsive
shopping (CS), and binge-eating (BE). Either alone or in co-
occurrence with the major ICDs, other repetitive and compulsive
behaviors have been observed (3, 4). These are referred as
impulsive-compulsive behaviors (ICBs) and include punding
(repetitive simple non goal-oriented behaviors), hobbyism
(repetitive complex behavior), and dopamine dysregulation
syndrome (DDS), which is a pattern of compulsive dopaminergic
medication use.
Prevalence rates of ICDs are similar in drug naïve PD patients
and in the general population (5, 6), but higher in medicated
PD patients (1, 2). The association between dopaminergic
medications and ICDs is now well-recognized (7), with an
increased risk for PD patients taking dopamine agonists alone or
together with levodopa (1, 8).
In addition to dopaminergic therapy, other demographic and
clinical variables may interact with exogenous and endogenous
dopaminergic levels, therefore increasing the susceptibility to
ICDs (8–10). Moreover, patients with ICDs report higher rates of
anhedonia (11), depression and anxiety (2, 12, 13), and cognitive
impairments (14, 15).
Cognitive deficits are common in PD and a significant
proportion is at risk to develop dementia (PDD) (16).
Evidence suggests that mild cognitive impairment in PD (PD-
MCI) is a frequent condition (17) and refers to a state
of cognitive alterations but preserved daily living autonomy,
therefore representing an intermediate stage between normal
cognition and dementia (18, 19). PD-MCI is characterized
by heterogeneous cognitive profile (20, 21) and cognitive
phenotypes may be differently associated with the presence and
severity of specific non-motor symptoms, possibly underlying
pathophysiological variability (22).
Both PD-MCI and PDD as well as ICD are well-recognized
cognitive and behavior conditions in PD. Since patients with
PD normal cognition (PD-NC), PD-MCI, and PDD differ
for demographic and clinical features, we might expect ICD
prevalence and characteristics to differ between these cognitive
categories. For example, in PDD the use of dopamine agonists
is discouraged due to the likelihood to develop psychosis
(23, 24) which in turn might result in reduced risk of ICD.
Younger age is one of the risk factors for ICD in PD (8),
possibly related to preserved ventral striatal responsiveness and
dopaminergic overstimulation (25). By contrast, PDD, who are
older than PD-NC and PD-MCI, might be less susceptible to
ICD. This concept would be also supported by a previous study
showing lower prevalence rates of dementia in patients with vs.
without ICD (26).
A recent meta-analysis showed worse performance of PD
patients with ICD in set-shifting and reward-related decision-
making tasks (15). To our knowledge, there are no studies on
ICDs prevalence across cognitive states and specific domains.
This is an important issue as recognizing factors associated
with ICD in PD across cognitive states and domains may
improve clinical diagnosis and pave the way for future studies
on therapeutic management. Considering the heterogeneous
cognitive profile disclosed by PD patients, we might expect
that ICD rates would change according to the cognitive
domains affected.
Here, for the first time, ICDs and related behaviors will be
described across PD patients with normal cognition (PD-NC),
PD-MCI, and PPD, and within specific cognitive phenotypes.
The study aims to investigate whether PD cognitive states
and phenotypes are associated with changes in prevalence and
severity of ICDs.
MATERIALS AND METHODS
Patients and Clinical Assessment
We recruited 600 consecutive patients with PD at the Parkinson’s
disease and Movement Disorders Unit, Neurology Clinic in
Padua, Italy, and IRCCS San Camillo Hospital in Venice,
between May 2010 and August 2018. All patients met the
clinical diagnostic criteria of the UK Parkinson’s Disease Society
Brain Bank (27). Exclusion criteria were diagnosis of atypical
Parkinsonism as well as clinically significant or unstable medical
conditions including cardiovascular, metabolic, psychiatric
diseases and neurosurgical procedures (including deep brain
stimulation). Among this large cohort, we included only PD
patients who underwent a comprehensive neuropsychological
evaluation according to Level II criteria (28, 29), and ICD
assessment with Minnesota Impulsive Disorder Interview
(MIDI) and the Questionnaire for Impulsive-Compulsive
Disorders in Parkinson’s Disease-Rating Scale (QUIP-RS) (30),
resulting in a sample of 326 PD patients (see Figure 1). Of note,
diagnosis of ICDs and ICBs were based on the MIDI, which was
administered by an experienced neuropsychologist. ICDs and
ICBs that were not included in the MIDI but were already well-
known to occur in the PD population were also investigated,
namely BE, punding, and DDS. All patients diagnosed with ICDs
answered affirmatively one gateway question plus an affirmative
answer to one or more of the remaining questions. In order
to evaluate ICDs severity, the QUIP-RS was also administered.
Finally, single and multiple ICDs and ICBs prevalence rates were
also investigated using publishedQUIP-RS cutoffs (30), following
a previous study of PD patients with ICDs in Italian cohorts (31).
Demographic information including sex, age, education,
age at symptoms onset, disease duration, and dopaminergic
medication were also collected. We calculated dopamine agonist
equivalent daily dose (DAED) and total L-dopa-equivalent daily
dose (LEDD) for each patient according to Tomlinson et al.
(32); further, DAED and LEDD were adjusted by body weight
(DAED/kg and LEDD/kg). Disease severity was assessed with
the motor part of the Movement Disorder Society Unified
Parkinson’s Disease Rating Scale (MDS-UPDRS-III) (33).
All subjects underwent a comprehensive assessment including
functional autonomy (by instrumental- and activity of daily
living, ADL/IADL) (34), subjective cognitive complaints and
their impact on daily functioning (by the Parkinson’s Disease—
Cognitive Functional Rating Scale, PD-CFRS) (35) and presence
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FIGURE 1 | Study flowchart. PD, Parkinson’s disease; PD-NC, PD with
normal cognition; PD-MCI, PD with mild cognitive impairment; PDD, PD with
dementia; ICD, impulse control disorder; QUIP-RS, Questionnaire for
Impulsive-Compulsive Disorders in Parkinson’s Disease-Rating Scale.
of depression, anxiety and the quality of life using the Beck
Depression Inventory (BDI-II), State-Trait Anxiety Inventory
forms (STAI-Y1 and Y2), and an 8-item version of the
Parkinson’s Disease Questionnaire for quality of life (PDQ-8),
respectively (36).
Patients underwent a comprehensive neuropsychological
battery as previously described (17), specifically designed to
target cognitive deficits in Parkinson’s disease with at least
two tests for each cognitive domain (e.g., attention and
working memory, executive, memory, language, and visuospatial
abilities) (28, 29).
We calculated z-scores for each test and participant, based
on standardized published Italian norms that are adjusted
for age and education, then PD patients were classified as
PD-MCI if z-score was at least 1.5 SD below appropriate
norms on at least two tests (i.e., within a single cognitive
domain or at least one test in two or more cognitive domains)
(28). Presence of PDD was assessed based on the Movement
Disorders Society Task force recommendations (29), which
included cognitive, daily functioning, and behavioral assessment.
Patients without cognitive alterations were defined as PD-
NC. Neuropsychological tests were performed on two separate
occasions within 5–7 days and administered in the morning
ON medication.
Finally, to investigate the association between presence of
ICDs and cognitive phenotypes, we selected a PD-subsample,
which was evaluated with the same cognitive battery, leaving a
final sample of 286 PD (see Figure 1).
Specifically, attention and working memory domain was
tested with the Trail Making Test part B-A (TMT B-A) (37)
and Digit Span Sequencing (DSS) of Wechsler Adult Intelligence
Scale–Fourth Edition (WAIS–IV) (38). Executive functions were
evaluated with the Stroop Color and Word test (39), and the
WAIS-IV similarities (38).Memory was assessed with the delayed
recall of Rey-Osterrieth complex figure test (ROCF) (40), and
prose memory tests (41). Language was tested with the semantic
fluency task, and Novelli’s naming test (42). Visuospatial and
visuoperceptive functions were assessed by Benton’s Judgment
of Line Orientation Test (43), and the Visual Object and Space
Perception incomplete letters recognition subtask (44).
Patients gave written informed consent, according to the
Declaration of Helsinki, before study enrolment, and ethical
approval was obtained from the Venice Research Ethics
Committee, Venice, Italy.
Statistical Analysis
Statistical analyses were performed using SPSS version 22
(IBM SPSS, Chicago, IL) (45). Demographic and clinical
continuous variables were analyzed using Kruskal-Wallis test,
with Mann–Whitney-U post-hoc test (p < 0.05) for between-
groups comparisons. Pearson’s Chi-square test was applied to
categorical variables. Frequencies of ICDs and related behaviors
across cognitive states were investigated using Pearson’s Chi-
square test. Linear trend of increase/decrease in frequency by
cognitive decline status was investigated using Chi-square test for
trend. ICDs severity and related behaviors across cognitive states
were compared between groups via ANCOVA model including
the continuous QUIP-RS score as dependent variable and as
covariate those demographic and clinical variables differing
between cognitive states, which has a significant effect on the
QUIP-RS continuous score in a multiple regression model.
Distribution normality was checked with Kolmogorov–Smirnov
tests and homogeneity of variance with Levene’s test.
Within each cognitive state, the frequencies of PD failing
two tests of the same cognitive domain were compared between
patients with (ICD+) and without (ICD–) ICDs/ICBs, using
Pearson’s Chi-square test. For all analyses, the significance
threshold was set at p < 0.05.
RESULTS
PD Demographic and Clinical
Characteristics Among Cognitive States
Out of 326 PD patients, 110 were cognitive normal (PD-NC), 163
had MCI (PD-MCI) and 53 dementia (PDD).
Mean age was different across subgroups (PDD>PD-
MCI>PD-NC, p< 0.0001) while gender distribution was similar.
PD-NC had lower age at symptoms onset, and higher years of
education than both PD-MCI and PDD groups (p < 0.0001 for
both variables). PDD had longer disease duration compared to
PD-NC and PD-MCI groups (p= 0.006).
The three PD cognitive subgroups did not differ for LEDD
and LEDD/kg. However, the DAED, the DAED/kg, and the
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percentage of patients under DA were lower in the PDD
group compared to PD-NC and PD-MCI groups (p = 0.0002,
p= 0.0001, p= 0.0005, respectively).
UPDRS-I and UPDRS-II scores were higher in the PDD,
but comparable in the PD-NC and PD-MCI (p = 0.0002 and
p < 0.0001, respectively). The UPDRS-III scores were different
across the three subgroups, with the lowest scores in PD-NC,
and the highest in PDD (p < 0.0001). Global cognitive status
(measured by mean of MMSE and MoCA scales) was different
across the three subgroups, with best cognitive performances
observed in PD-NC and worst in PDD (p < 0.0001 for both
variables). BDI-II scores differed across the three subgroups,
with the lowest value in PD-NC and the highest in the PPD
(p < 0.0001). However, the percentage of patients with BDI-II
score above the cutoff (>14) was higher in PDD (p = 0.0027),
but comparable in the PD-NC and PD-MCI. State (STAI-Y1), but
not trait (STAI-Y2) anxiety score, was higher in PDD compared
to PD-NC and PD-MCI (p= 0.0076). PDD had greater disability
on ADL/IADL compared to PD-NC and PD-MCI groups
(p < 0.0001 and p < 0.0002, respectively). Finally, functional
disability due to mainly cognitive impairments (PD-CFRS) was
significantly different across PD cognitive subgroups (PDD>PD-
MCI>PD-NC) (p < 0.0001). Demographic and clinical data are
reported in Supplementary Table 1.
Demographic and Clinical Characteristics
Associated With ICD Among
Cognitive States
Out of 326 PD patients, 60 PD-NC patients, 81 PD-MCI patients,
and 22 PDD patients were diagnosed with presence of at least one
ICD or ICB.
In PD-NC, ICD+, and ICD– did not differ for mean age,
gender distribution, education level, and age at symptoms onset,
although ICD+ had longer disease duration (p= 0.0017). LEDD
and LEDD/Kg were higher in the ICD+ (p = 0.0002 and
p = 0.0001, respectively), but there were no differences in the
DAED, DAED/Kg, and in the percentage of patients under DA.
In PD-MCI, ICD+ had lower mean age and age at symptoms
onset, and longer disease duration than ICD– (p = 0.0142,
p < 0.0001, and p = 0.0003, respectively). LEDD, LEDD/Kg,
DAED, DAED/Kg, and the percentage of patients under DA were
higher in the ICD+ compared to ICD– (p = 0.0028, p = 0.0156,
p= 0.0305, p= 0.0469, and p= 0. 0013, respectively).
In both PD-NC and PD-MCI, the quality of life of ICD+
patients was worse (p = 0.0009 and p = 0.0052, respectively).
Conversely, UPDRS-I, UPDRS-II, and UPDRS-III scores, global
cognitive status (measured by MMSE and MoCA scales), BDI-
II score and percentage of patients with BDI-II score above the
cutoff, state and trait anxiety (STAI-Y1 and STAI-Y2 scores),
disability on the ADL, IADL, and PD-CFRS scales did not differ
between ICD+ and ICD–.
In the PDD, there were no difference between ICD+ and
ICD– in any demographic and clinical characteristic investigated.
Demographic and clinical data of ICD+ and ICD– among
cognitive states are reported in Table 1.
ICDs Presence and Severity Across
Cognitive States
According to the MIDI, ICDs, and/or ICBs were present in 55%
(60 patients) of PD-NC, in 50% (81 patients) of PD-MCI, and
in 42% (22 patients) of PDD. Results are reported in details in
Table 2 and Figure 2.
Frequencies decrease across cognitive states, but trend toward
a decrease of frequencies with cognitive decline do not reach
statistical significance (p= 0.34).
According to the QUIP-RS, either ICDs or ICBs above the
cutoff were present in the 24% of PD-NC, in the 24% of PD-MCI,
and in the 23% of PDD. The 20% of PD-NC, the 20% of PD-MCI,
and the 21% of PDD, presented both ICDs and ICBs.
Considering QUIP-RS scores above 0, either ICDs or ICBs
were present in the 54% of PD-NC, in the 49% of PD-MCI, and
in 42% of PDD.
Severity of ICD+ did not differ across cognitive states
(p= 0.877). No differences were also observed considering ICDs
and ICBs separately (p = 0.769 and p = 0.329, respectively)
(see Table 2).
ICDs and Cognitive Phenotypes
In the PD-NC group, there were no differences between the
percentages of ICD+ and ICD– failing two tests of the same
cognitive domain.
In PD-MCI, there was higher number of ICD+ patients failing
two tests of attention (ICD+: 20% vs. ICD–: 4%; p = 0.031)
(see Table 3). Percentage of patients with TMT B-A z-scores
below 1.5 SD was significantly higher in the ICD+ than in the
ICD– subgroup (ICD+: 41%; ICD–: 24%; p = 0.035), with no
differences in the DSS performances (see Table 4).
In PDD, there were higher rates of ICD+ patients failing
two tests of executive function (ICD+: 44% vs. ICD–: 30%;
p= 0.027), with no differences in the other domains (seeTable 3).
Data seems to be driven by the Similarities task as the percentage
of patients with z-scores below 1.5 SD was significantly higher in
the ICD+ than in the ICD– subgroup (ICD+: 67%; ICD–: 29%;
p= 0.035), with no differences in the Stroop task (see Table 4).
Detailed demographic characteristics of PD-MCI group
based on performances at TMT B-A test and PDD based
on performance at Similarities task are provided in the
Supplementary Tables 2, 3.
DISCUSSION
This is the first study describing prevalence and characteristics of
ICDs and related behaviors in PD cognitive states including both
PD with dementia and PD-MCI. We found that their prevalence
tends to decrease from PD-NC to PDD, although differences
in rates were not significant while severity was similar across
cognitive states.
These findings are different from other studies reporting an
association with cognitive performance (14, 15) and particularly
with one prevalence study in which ICDs were less frequent in
PDD compared to PD-NC (26). Discrepancies with the latter
study, may reflect differences in PDD diagnostic procedures
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TABLE 1 | Demographic and clinical characteristics of ICD+ and ICD– across PD cognitive states.
PD-NC
(n = 110)
PD-MCI
(n = 163)
PDD
(n = 53)
ICD+ vs. ICD-
ICD+
n = 60
ICD–
n = 50
ICD+
n = 81
ICD–
n = 82
ICD+
n = 22
ICD–
n = 31
PD-NC PD-MCI PDD
Age (yr) 60.58 (9.36) 61.48 (10.49) 67.24 (8.61) 70.27 (8.93) 71.50 (9.39) 74.10 (7.53) 0.5991 0.0142 0.3199
Sex (%, male) 49% 59% 68% 55% 67% 71% 0.4007 0.1356 0.9812
Education (yr) 12.80 (3.82) 12.70 (4.35) 9.45 (4.45) 9.85 (4.46) 9.91 (4.85) 8.55 (4.65) 0.8657 0.4991 0.1901
Age of onset symptoms (yr) 51.45 (10.36) 54.56 (10.32) 55.55 (10.20) 62.67 (10.48) 59.22 (10.40) 63.17 (9.67) 0.1604 <0.0001 0.2032
Disease duration (yr) 9.12 (4.54) 6.08 (5.45) 10.85 (6.55) 7.10 (5.09) 11.50 (5.19) 11.00 (5.15) 0.0017 0.0003 0.8432
LEDD 963.06 (476) 589.40 (507.28) 973.90 (492.03) 750.54 (526.12) 814.06 (416.35) 655.86 (380.37) 0.0002 0.0028 0.1405
LEDD/kg 14.00 (7.91) 8.10 (6.75) 13.45 (7.04) 11.00 (8.19) 10.98 (5.78) 8.76 (4.73) 0.0001 0.0156 0.1711
DA (%) 80% 73% 90% 67% 57% 52% 0.5684 0.0013 0.9418
DAED 157.37 (110.42) 132.16 (117.06) 141.46 (95.05) 110.30 (113.62) 79.95 (96.07) 78.15 (87.52) 0.2786 0.0305 0.8610
DAED/kg 2.29 (1.77) 1.86 (1.65) 1.97 (1.41) 1.65 (1.85) 1.06 (1.24) 1.03 (1.16) 0.3143 0.0469 0.8015
MDS-UPDRS-I 10.57 (5.41) 9.24 (5.51) 11.19 (4.89) 9.29 (4.44) 13.88 (7.47) 16.73 (7.57) 0.3944 0.0748 0.5597
MDS-UPDRS-II 11.67 (6.43) 9.43 (6.47) 14.29 (6.94) 11.62 (6.37) 19.50 (4.31) 19.47 (8.93) 0.1137 0.0972 0.7465
MDS-UPDRS-III 20.75 (12.64) 18.00 (12.76) 28.52 (11.72) 24.67 (12.84) 37.46 (10.38) 33.69 (13.06) 0.2177 0.0894 0.3347
ADL 5.74 (0.60) 5.83 (0.81) 5.43 (1.01) 5.35 (0.96) 4.39 (1.33) 3.52 (1.91) 0.1045 0.4780 0.1441
IADL 5.96 (1.44) 5.95 (1.66) 5.45 (1.66) 5.64 (1.64) 3.39 (1.58) 2.85 (1.81) 0.8489 0.3608 0.3357
PD-CFRS 2.24 (2.23) 1.42 (1.75) 4.61 (4.16) 3.40 (3.35) 10.88 (5.28) 13.87 (6.97) 0.1025 0.1495 0.2153
PDQ-8 9.60 (5.29) 5.80 (4.23) 10.93 (5.30) 8.47 (5.33) 12.56 (6.44) 14.18 (5.53) 0.0009 0.0052 0.3974
STAI-Y1 37.82 (11.47) 37.97 (8.58) 38.86 (10.58) 39.62 (10.09) 42.25 (11.05) 44.05 (8.98) 0.4616 0.6162 0.4636
STAI-Y2 41.79 (10.80) 41.00 (9.49) 41.25 (10.40) 41.58 (10.63) 44.94 (11.80) 45.45 (10.54) 0.7461 0.9260 0.7499
BDI-II 9.10 (8.02) 8.35 (6.60) 10.62 (7.05) 10.77 (8.26) 12.80 (7.06) 15.54 (7.40) 0.9235 0.7234 0.2616
BDI-II (%, cutoff > 14) 18% 16% 28% 28% 40% 54% 0.9775 0.8829 0.5263
MoCA 27.52 (2.06) 27.55 (1.86) 25.98 (2.82) 25.62 (2.18) 21.37 (4.30) 21.10 (4.36) 0.7254 0.2793 0.6006
MMSE 25.89 (2.39) 25.04 (2.65) 22.30 (3.52) 22.00 (2.95) 15.68 (4.85) 17.17 (3.66) 0.1248 0.5933 0.3682
Significant differences (p < 0.05) are reported in bold type. SD, standard deviation; PD, Parkinson’s disease; PD-NC, PD with normal cognition; PD-MCI, PD with mild cognitive
impairment; PDD, PD with dementia; ICD+, patients with impulse control disorders and related behaviors according to MIDI; ICD-, patients without impulse control disorders and
related behaviors according to MIDI; MDS-UPDRS, Movement Disorder Society Unified Parkinson’s Disease Rating Scale; LEDD, levodopa equivalent daily dose; DAED, dopamine
agonist equivalent dose; LEDD/kg, LEDD adjusted by body weight; DAED/kg, DAED adjusted by body weight; ADL, Activity of daily living; IADL, Instrumental activities of daily living;
PD-CFRS, Parkinson’s Disease—Cognitive Functional Rating Scale; PDQ-8, Parkinson’s Disease Questionnaire; STAI (Y-1, Y-2), State-Trait Anxiety Inventory; BDI-II, Beck Depression
Inventory-II; MoCA, Montreal Cognitive Assessment; MMSE, Mini Mental State Examination.
(46). In our cohort all patients underwent level II cognitive,
daily functioning and behavioral assessments, and cognitive
states diagnosis included PD-MCI as well as PD-NC and PDD,
following proposed criteria for PD (28, 29).
Indeed clinical and demographic characteristics in our cohort
of PD-NC, PD-MCI, and PDD are in line with literature, and
this was indirectly confirmed by the observation of older age,
longer disease duration, worse motor symptomatology, cognitive
decline, and depression levels in our PDD (16, 47, 48).
In our study, diagnosis of ICDs or ICBs was based on the
MIDI and behaviors that were not included in the MIDI but
commonly occur in PD were also investigated. The QUIP-RS,
since it has not been validated in the Italian population, was used
only for assessing severity. In order to characterize the type of
ICDs and ICBs of our sample, data were also presented according
to published US sample cutoff score (30) further validated in the
German population (49). According to published cutoff scores
(30), pure single ICDs were not present in any patient in our
cohort. This may imply either that QUIP-RS cutoff scores are
too conservative for Italian population, or that ICDs infrequently
occur as single entity. In any case, future studies are needed to
further explore this point.
Exploring ICDs frequency based on scores of QUIP-RS>0,
we found similar results. Of note, frequencies of HS and BE
were similar in PDD and in PD-NC regardless of lower DAED
levels and lower number of patients on dopamine agonists (8,
23, 24, 50, 51). We speculate that similar rates might be either
due to (i) shared underlying mechanisms (i.e., dementia-like
neurodegenerations vs. ICDs-related) or (ii) the characteristics of
QUIP-RS, which may capture features of disinhibitions related
to impulsivity without ruling out dementia-like behavioral
disinhibition (50, 52).
Our study confirms, in PD-NC and PD-MCI, previously
reported risk factors for ICD. In the PD-NC group, ICD
was associated with higher disease duration and LEDD. In
the PD-MCI, ICD was associated with lower age and age at
symptoms onset, and higher disease duration, LEDD, DAED, and
percentage of patients under DA. Conversely, ICD+ and ICD–
PDD patients did not differ in any demographic and clinical
variable investigated. For a clinical point of view, these finding
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FIGURE 2 | Frequency of ICDs and ICBs among cognitive states. Slopes of the trend lines are reported. PD, Parkinson’s disease; PD-NC, PD with normal cognition;
PD-MCI, PD with mild cognitive impairment; PDD, PD with dementia; ICD, impulse control disorder; ICB, impulsive compulsive behavior.
TABLE 3 | Frequencies of patients with a failure in at least two tests within a cognitive domain across cognitive states and ICD-subgroups.
Cognitive domains PD-MCI
(n = 147)
PDD
(n = 49)
PD-MCI PDD
ICD–
(n = 75) (%)
ICD+
(n = 72) (%)
ICD–
(n = 29) (%)
ICD+
(n = 20) (%)
P-value
ICD+ vs. ICD-
Attention/working memory 4 20 76 73 0.0315 0.8453
Executive 5 4 30 44 0.8550 0.0279
Language 3 0 26 36 0.4970 0.8687
Memory 2 9 48 47 0.2246 0.7930
Visuospatial 22 27 80 81 0.7241 0.7138
Significant differences (p < 0.05) are reported in bold type. PD, Parkinson’s disease; PD-NC, PD with normal cognition; PD-MCI, PD with mild cognitive impairment; PDD, PD with
dementia; ICD+, patients with impulse control disorders and related behaviors according to MIDI; ICD-, patients without impulse control disorders and related behaviors according
to MIDI.
suggest that i) ICD are equally common in PDD as PD-NC and
PD-MCI, and that ii) the recognized risk factors for ICD in PD
may not apply to PDD, further encouraging physician awareness.
Furthermore, quality of life, as assessed by PDQ-8, differs
between ICD+ and ICD- in PD-NC and PD-MCI as previously
reported (13). Interestingly, we do not find any difference in
PDQ-8 score of PDD patients with and without ICDs maybe
because other motor and/or non-motor symptoms are likely to
impact more than ICDs on QoL.
Despite frequencies and severities of ICDs were similar across
PD-NC, PD-MCI and PDD, patterns of cognitive alterations
(i.e., failure in two tests of the same domain), associated with
presence/absence of ICDs, differed within each cognitive state.
Presence of ICDs in PD-MCI is associated with attention
impairments, whilst in PDD with ICDs cognitive decline
involved the executive domain. In PD-NC, there were no
patterns of cognitive alterations and this reflects the MDS
guidelines, with failure in two tests of the same cognitive
domain indicative of PD-MCI (28). Taken together these findings
support frontal-striatal (i.e., executive and attentive) instead of
posterior impairments (i.e., language and visuospatial abilities) in
ICD+ (53–55) and the involvement of altered mesocorticolimbic
activity (56–58). Moreover, this study further extends previous
results showing that the patterns of frontal dysfunctions of
ICD+ differ within each cognitive state. Clinically, these results
have important implications as attentive impairments in PD-
MCI and executive dysfunctions in PDD measured by level II
neuropsychological assessment may suggest co-presence of ICDs
and related behaviors.
When performances were analyzed considering the single
neuropsychological test, the TMT B-A but not the DSS
was associated with higher rates of ICD+ in PD-MCI.
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TABLE 4 | Percentage of ICD+ and ICD– across cognitive states with a cognitive performance below 1.5 SD, in the attentive and executive domains.
PD-MCI PDD PD-MCI PDD
ICD– (%) ICD+ (%) ICD– (%) ICD+ (%) P-value
ATTENTION AND WORKING MEMORY DOMAIN
TMT B-A 24 41 79 60 0.0350 0.2500
DSS (WAIS-IV) 13 15 58 75 0.9190 0.3790
EXECUTIVE DOMAIN
Stroop test 46 49 75 89 0.9141 0.4609
Similarities 15 18 29 67 0.8948 0.0355
Significant differences (p < 0.05) are reported in bold type. PD, Parkinson’s disease; PD-NC, PD with normal cognition; PD-MCI, PD with mild cognitive impairment; PDD, PD with
dementia; ICD+, patients with impulse control disorders and related behaviors according to MIDI; ICD–, patients without impulse control disorders and related behaviors according to
MIDI; TMT B-A, Trail Making Test part B-A; DSS, Digit Span Sequencing subtest of the Wechsler Adult Intelligence Scale–Fourth Edition; SD, standard deviation.
Worse TMT-B-A performances have been reported in non-PD
pathological gamblers (59) and in PD patient with ICDs (53, 60,
61), although no specifically investigated within cognitive states.
The TMT B-A and the DSS, albeit being categorized within the
attentive domain are tasks investigating set-shifting and working
memory abilities, respectively. TMT B-A requires cognitive
flexibility in order to switch from numerical to alphabetical
sequences, which is an important ability for maintaining goal-
oriented behaviors when facing environmental changes or
task demands in daily life (62). In lesion mapping studies,
TMT B-A performances are associated with rostral anterior
cingulate cortex (63), which is part of the mesocorticolimbic
pathway mediating the control of reward-related behaviors that
may be overstimulated by dopaminergic medication. In the
early stages of the PD, dopaminergic depletion is relatively
circumscribed to the dorsal striatum, whilst the limbic (nucleus
accumbens) and cortical (prefrontal cortex) structures are
relatively spared and only degenerate in the later stages (64).
Medication levels necessary to restore dopaminergic depletion in
the dorsal striatummay abnormally stimulate mesocorticolimbic
structures. Interestingly, deficits in the TMT B-A task are more
common in PD-MCI patients with lower age and lower age
at symptoms onset, longer disease duration, higher DEAD and
LEDD levels, and higher percentage of dopamine agonists use
(see Supplementary Table 2) who may be more vulnerable to
the overdosing effect of medication. The TMT B-A, albeit being
a sensitive test of ICD+ in PD-MCI, may not be indicated for
assessing PDD patients. In our sample, high number of PDD
patients was not able to perform either the TMT B-A or the DDS.
In PDD patients, performance in the Similarities but not
the Stroop tasks was associated with ICD+. Lack of differences
between ICD+ and ICD– patients in the Stroop task (2, 53, 54, 65,
66) as well as in the Similarities task (53, 65) have been reported,
although in these studies dementia was an exclusion criteria.
This may explain why we found that ICD+ was associated
with impairments in the Similarities task contrarily the previous
results (53, 65). Compared to the Stroop task that evaluates verbal
inhibition, the similarities task assesses abstract thinking, concept
formation, and verbal reasoning as participants are instructed
to describe how two things are similar. Abstract thinking is
associated with anterior prefrontal, fronto-parietal cortices, and
insula functioning (63). Therefore, we might speculate that, as
PD cognitive severity increases, presence of ICDs is associated
with wider cortical and subcortical dysfunctions which target
limbic and frontal and parietal areas. PDD patients who fail the
Similarities task present worse general cognitive performance
and higher levels of trait anxiety (see Supplementary Table 3).
Although the study was conducted in a large cohort
of PD patients following proposed guidelines for PD-MCI
and PDD diagnosis, there are some limitations that should
be acknowledged.
First, participants were recruited during clinics and this
limits the generalizability of the results to the whole PD
population. Second, the QUIP-RS has not been validated in the
Italian population therefore prevalence rates of ICDs according
to QUIP-RS cutoff scores should be considered cautiously
as may not apply for our sample. However, patients were
categorized as ICD+ by an experiencing neuropsychologist who
also administered the MIDI and clinical diagnosis was done
according to established diagnostic criteria. Third, in PDD,
lack of differences between ICD+ and ICD- in the attentive
domain might be biased by the floor effect of the TMT B-
A and DSS, with high number of PDD patients not able
to perform the tasks. Fourth, the TMT B-A and Similarities
tasks are not purely attentive and executive, but they also
investigate executive functions and language, respectively (67).
However, we might exclude a language involvement in PDD
with ICD as performances in semantic fluencies and naming
did not differ between ICD+ and ICD–. Further studies should
use experimental tasks investigating specific cognitive processes
to assess neurological underpinnings of ICDs and medication
effects across cognitive states and domains.
In conclusion, our findings provide evidence that cognitive
states per sè are not associated with (i) the presence and
the (ii) severity of ICDs and related behaviors. Conversely,
(iii) impairments in ICD+ are circumscribed to attentive and
executive domains in PD-MCI and PDD patients, respectively.
Finally, (iv) the TMT B-A task for the attention and
working memory domain in PD-MCI, and the Similarities
task for the executive function domain in the PDD were the
tasks more sensitive of ICD and related behavior presence.
Taken together these findings may suggest different ICDs
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entities according to disease cognitive progression. Namely,
a relative early phase dopamine agonist dependent ICDs
characterized by mainly attentive problems and a late phase
medication independent ICDs characterized by wider cortical
and dysexecutive dysfunctions. Future studies should help
addressing this hypothesis.
PD patients should be carefully interviewed for the presence
of ICDs and related behaviors at any stage of the disease,
as being diagnosed either with PD-MCI, PDD, or being
PD-NC is not indicative per sè of a higher or lower risk
of ICD.
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